Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Unified understanding of MS course is required for drug development

The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. [No authors listed.] FDA approves new drug to treat multiple sclerosis. US Food and Drug Administration https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm (2017).

  2. [No authors listed.] New medicine for multiple sclerosis. European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002847.jsp&mid=WC0b01ac058004d5c1 (2017).

  3. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

    Article  Google Scholar 

  4. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (European Medicines Agency, 2015).

  5. U.S. Food and Drug Administration. Ocrelizumab Summary Review. US Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000SumR.pdf (2017).

Download references

Acknowledgements

A.J.T. acknowledges support from the UCL/UCLH National Institute of Health (NIHR) Biomedical Research Centre (BRC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alan J. Thompson.

Ethics declarations

Competing interests

A.J.T. is chair and T.C. a member of the International Progressive MS Alliance Scientific Steering Committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coetzee, T., Thompson, A. Unified understanding of MS course is required for drug development. Nat Rev Neurol 14, 191–192 (2018). https://doi.org/10.1038/nrneurol.2017.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.184

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research